POLR3B is associated with a developmental and epileptic encephalopathy with myoclonic-atonic seizures and ataxia

Joseph D Symonds^{1

2}, Kristen L Park³, Cyril Mignot⁴, Stewart Macleod², Martin Armstrong⁵, Houman Ashrafian^{6

7}, Geneviève Bernard^{8

9

10}, Kathleen Brown¹¹, Andreas Brunklaus^{1

2}, Mary Callaghan¹², Georg Classen¹³, Julie S Cohen^{14

15}, Ioana Cutcutache¹⁶, Jean-Madeleine de Sainte Agathe¹⁷, David Dyment¹⁸, Katherine S Elliot¹⁹, Arnaud Isapof²⁰, Shelagh Joss²¹, Boris Keren¹⁷, Michael Marble²², Amy McTague²³, Matthew Osmond¹⁸, Matthew Page¹⁶, Marc Planes^{24

25

26}, Konrad Platzer²⁷, Sylvia Redon^{24

25

26}, James Reese²⁸, Margarita Saenz¹¹, Constance Smith-Hicks^{14

15}, Daniel Stobo²¹, Christian Stockhaus²⁷, Marie-Laure Vuillaume^{25

29

30}, Nicole I Wolf³¹, Emma L Wakeling³², Grace Yoon³³, Julian C Knight¹⁹, Sameer M Zuberi^{1

2}

Affiliations

¹ Paediatric Neurosciences Research Group, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
² Royal Hospital for Children, Glasgow, UK.
³ Children's Hospital Colorado, Anschutz Medical Campus, University of Colorado, Aurora, Colorado, USA.
⁴ Département de Génétique, Groupe Hospitalier Pitié-Salpêtrière-Hôpital Trousseau, Sorbonne Université, Paris, France.
⁵ UCB Pharma, Braine l'Alleud, Belgium.
⁶ Division of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK.
⁷ Department of Experimental Therapeutics, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK.
⁸ Departments of Neurology and Neurosurgery, Pediatrics and Human Genetics, McGill University, Montreal, Quebec, Canada.
⁹ Department Specialized Medicine, Division of Medical Genetics, McGill University Health Centre, Montreal, Quebec, Canada.
¹⁰ Child Health and Human Development Program, Research, Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
¹¹ Department of Pediatrics, Section of Genetics and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.
¹² Department of Paediatrics, University Hospital Wishaw, Wishaw, UK.
¹³ Children's Center Bethel, University Bielefeld, Bielefeld, Germany.
¹⁴ Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland, USA.
¹⁵ Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
¹⁶ UCB Pharma, Slough, UK.
¹⁷ Department of Genetics, Pitié-Salpêtrière Hospital, APHP. Sorbonne Université, Paris, France.
¹⁸ Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada.
¹⁹ Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
²⁰ Service de Neuropédiatrie, Hôpital Trousseau, Sorbonne Université, Paris, France.
²¹ West of Scotland Regional Genetics Service, Queen Elizabeth University Hospitals, Glasgow, UK.
²² Division of Pediatric Genetics, Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
²³ Developmental Neurosciences. Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, London, UK.
²⁴ Service de Génétique Médicale et Biologie de la Reproduction, CHU de Brest, Brest, France.
²⁵ Laboratoire de Biologie Médicale Multi-Sites SeqOIA, Paris, France.
²⁶ Université Brest, Brest, France.
²⁷ Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
²⁸ Presbyterian Healthcare System, Albuquerque, New Mexico, USA.
²⁹ UMR 1253, iBrain, University of Tours, Tours, France.
³⁰ Genetics Department, University of Tours, Tours, France.
³¹ Department of Child Neurology, Amsterdam Leukodystrophy Center, Emma's Children's Hospital, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
³² North East Thames Regional Genetic Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
³³ Departments of Paediatrics and Molecular Genetics, Hospital for Sick Children, Toronto, Ontario, Canada.

PMID: 39348199
DOI: 10.1111/epi.18115

POLR3B is associated with a developmental and epileptic encephalopathy with myoclonic-atonic seizures and ataxia

Joseph D Symonds et al. Epilepsia. 2024 Nov.

. 2024 Nov;65(11):3303-3323.

doi: 10.1111/epi.18115. Epub 2024 Sep 30.

Authors

Affiliations

¹ Paediatric Neurosciences Research Group, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
² Royal Hospital for Children, Glasgow, UK.
³ Children's Hospital Colorado, Anschutz Medical Campus, University of Colorado, Aurora, Colorado, USA.
⁴ Département de Génétique, Groupe Hospitalier Pitié-Salpêtrière-Hôpital Trousseau, Sorbonne Université, Paris, France.
⁵ UCB Pharma, Braine l'Alleud, Belgium.
⁶ Division of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK.
⁷ Department of Experimental Therapeutics, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK.
⁸ Departments of Neurology and Neurosurgery, Pediatrics and Human Genetics, McGill University, Montreal, Quebec, Canada.
⁹ Department Specialized Medicine, Division of Medical Genetics, McGill University Health Centre, Montreal, Quebec, Canada.
¹⁰ Child Health and Human Development Program, Research, Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
¹¹ Department of Pediatrics, Section of Genetics and Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.
¹² Department of Paediatrics, University Hospital Wishaw, Wishaw, UK.
¹³ Children's Center Bethel, University Bielefeld, Bielefeld, Germany.
¹⁴ Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland, USA.
¹⁵ Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
¹⁶ UCB Pharma, Slough, UK.
¹⁷ Department of Genetics, Pitié-Salpêtrière Hospital, APHP. Sorbonne Université, Paris, France.
¹⁸ Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada.
¹⁹ Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
²⁰ Service de Neuropédiatrie, Hôpital Trousseau, Sorbonne Université, Paris, France.
²¹ West of Scotland Regional Genetics Service, Queen Elizabeth University Hospitals, Glasgow, UK.
²² Division of Pediatric Genetics, Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
²³ Developmental Neurosciences. Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, London, UK.
²⁴ Service de Génétique Médicale et Biologie de la Reproduction, CHU de Brest, Brest, France.
²⁵ Laboratoire de Biologie Médicale Multi-Sites SeqOIA, Paris, France.
²⁶ Université Brest, Brest, France.
²⁷ Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
²⁸ Presbyterian Healthcare System, Albuquerque, New Mexico, USA.
²⁹ UMR 1253, iBrain, University of Tours, Tours, France.
³⁰ Genetics Department, University of Tours, Tours, France.
³¹ Department of Child Neurology, Amsterdam Leukodystrophy Center, Emma's Children's Hospital, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
³² North East Thames Regional Genetic Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
³³ Departments of Paediatrics and Molecular Genetics, Hospital for Sick Children, Toronto, Ontario, Canada.

PMID: 39348199
DOI: 10.1111/epi.18115

Abstract

Objective: POLR3B encodes the second largest subunit of RNA polymerase III, which is essential for transcription of small non-coding RNAs. Biallelic pathogenic variants in POLR3B are associated with an inherited hypomyelinating leukodystrophy. Recently, de novo heterozygous variants in POLR3B were reported in six individuals with ataxia, spasticity, and demyelinating peripheral neuropathy. Three of these individuals had epileptic seizures. The aim of this article is to precisely define the epilepsy phenotype associated with de novo heterozygous POLR3B variants.

Methods: We used online gene-matching tools to identify 13 patients with de novo POLR3B variants. We systematically collected genotype and phenotype data from clinicians using two standardized proformas.

Results: All 13 patients had novel POLR3B variants. Twelve of 13 variants were classified as pathogenic or likely pathogenic as per American College of Medical Genetics (ACMG) criteria. Patients presented with generalized myoclonic, myoclonic-atonic, atypical absence, or tonic-clonic seizures between the ages of six months and 4 years. Epilepsy was classified as epilepsy with myoclonic-atonic seizures (EMAtS) in seven patients and "probable EMAtS" in two more. Seizures were treatment resistant in all cases. Three patients became seizure-free. All patients had some degree of developmental delay or intellectual disability. In most cases developmental delay was apparent before the onset of seizures. Three of 13 cases were reported to have developmental stagnation or regression in association with seizure onset. Treatments for epilepsy that were reported by clinicians to be effective were: sodium valproate, which was effective in five of nine patients (5/9) who tried it; rufinamide (2/3); and ketogenic diet (2/3). Additional features were ataxia/incoordination (8/13); microcephaly (7/13); peripheral neuropathy (4/13), and spasticity/hypertonia (6/13).

Significance: POLR3B is a novel genetic developmental and epileptic encephalopathy (DEE) in which EMAtS is the predominant epilepsy phenotype. Ataxia, neuropathy, and hypertonia may be variously observed in these patients.

Keywords: Encephalopathy; Epilepsy; Genetic; Myoclonic‐atonic seizures; POLR3B.

PubMed Disclaimer

References

REFERENCES

1. Symonds JD, Elliott KS, Shetty J, Armstrong M, Brunklaus A, et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio‐economic determinants. Brain. 2021;144:2879–2891.
1. Symonds JD, Zuberi SM, Stewart K, Mclellan A, O'Regan M. Macleod S. Incidence and phenotypes of childhood‐onset genetic epilepsies: a prospective population‐based national cohort. Brain. 2019;2019(142):2303–2318.
1. Trump N, McTagueA BH, Papandreou A, Meyer E, et al. Improving diagnosis and broadening the phenotypes in early‐onset seizure and severe developmental delay disorders through gene panel analysis. J Med Genet. 2016;53:310–317.
1. Symonds & McTague. Epilepsy and developmental disorders: next generation sequencing in the clinic. Eur J Paediatr Neurol. 2020;24:15–23.
1. Truty R, Patil N, Sankar R, Sullivan J, Millichap J, et al. Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy. Epilepsia Open. 2019;397:397–408.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

POLR3B is associated with a developmental and epileptic encephalopathy with myoclonic-atonic seizures and ataxia

Affiliations

POLR3B is associated with a developmental and epileptic encephalopathy with myoclonic-atonic seizures and ataxia

Authors

Affiliations

Abstract

References

REFERENCES

MeSH terms

Substances

LinkOut - more resources

Full Text Sources